O-017 A Phase I/II trial of erlotinib (ERLO) in higher-risk MDS after azacitidine (AZA) failure

Authors :: Sylvain Thepot
Jacques Delaunay
Stefan Wickenhauser
Francois Dreyfus
Emmanuel Raffoux
Odile Beyne-Rauzy
Eric Wattel
Aline Schmidt
Pierre Fenaux
S. Boehrer
Thomas Prebet
Lionel Adès
Source :: Leukemia Research. 37:S16-S17
Publication Year :: 2013
Publisher :: Elsevier BV, 2013.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Phase i ii
business.industry
Internal medicine
Azacitidine
medicine
Hematology
Erlotinib
business
medicine.drug

Tools